Janssen Reports Results of Tremfya (guselkumab) in P-III DISCOVER-1 & 2 Trials for the Treatment of Active Psoriatic Arthritis
Shots:
- The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739 patients with active PsA including those previously treated with a biologic anti-TNF alpha agent
- The results showed that Tremfya inhibited radiographic progression & maintained low rates of progression @ 2yrs. in biologic-naïve patients, improvements in joints, axial symptoms, enthesitis, dactylitis & an improvement in pain with 32% & 33% of patients achieved =20% & =50 % improvement @16wks.
- The safety profile was consistent b/w adults with active PsA @ 2yrs. & adults with PsO through 5yrs. The therapy is approved in the US, Canada, Japan, & other countries globally for plaque PsO & active PsA
Ref: PR Newswire | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com